|
Malignant neoplasm of breast
|
0.550 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Duodenal Ulcer
|
0.410 |
Biomarker
|
disease |
HPO |
|
|
|
|
Gastric ulcer
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ulcer of esophagus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Iron deficiency anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Impaired platelet aggregation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Decreased serum thromboxane B2
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
PHOSPHOLIPASE A2, GROUP IVA, DEFICIENCY OF
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Human cardiac muscle magnesium and potassium concentrations: can skeletal muscle, mononuclear blood cells, erythrocyte and plasma concentrations provide a surrogate measure?
|
1642455 |
1992 |
|
Crohn Disease
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
The results of this study showed that (a) three months after ileocolonic resection for Crohn's disease the neoterminal ileal mucosa showed endoscopically new inflammation and had higher PLA2 activity than at the time of the operation (n = 8); no such findings were seen in controls (n = 7), (b) histologically normal ileal mucosa (n = 3) contained mRNA for three isoforms of PLA2 (PLA2-I, PLA2-II, and cPLA2), but the amounts of PLA2-II mRNA clearly exceeded the amounts of mRNA for PLA2-I and cPLA2, (c) ileal mucosa from Crohn's patients (n = 2) contained higher values of PLA2-II mRNA than ileal mucosa from two controls, (d) ileal mucosa from Crohn's patients (n = 4) showed increased PLA2-II mRNA three months after ileocolonic resection.
|
7590434 |
1995 |
|
Hyperglycemia
|
0.200 |
Biomarker
|
disease |
RGD |
These data indicated that hyperglycemia is inhibiting Na+,K(+)-ATPase activity by the sequential activation of PKC and cPLA2, resulting in the liberation of arachidonic acid and increased the production of PGE2, which are known inhibitors of Na+,K(+)-ATPase.
|
7635966 |
1995 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR analysis demonstrated that four of the investigated pre-B-ALL clones expressed the gene coding for cytosolic phospholipase A2 (cPLA2), but not the gene coding for 5-lipoxygenase.
|
7646998 |
1995 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR analysis demonstrated that four of the investigated pre-B-ALL clones expressed the gene coding for cytosolic phospholipase A2 (cPLA2), but not the gene coding for 5-lipoxygenase.
|
7646998 |
1995 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachindonic acid, is associated with schizophrenia.
|
8873778 |
1996 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We review a recent study which suggests that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid (AA), is associated with schizophrenia.
|
8888134 |
1996 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.
|
9169405 |
1997 |
|
Squamous cell carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells.
|
9247974 |
1997 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene.
|
9323323 |
1997 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A blood sample was also taken from the same population to test for allelic association between schizophrenia and a polymorphism close to the promoter site of the cytosolic phospholipase-A2 gene which is mapped to chromosome 1q25.
|
9689723 |
1998 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia.
|
9800222 |
1998 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, the supply of arachidonic acid provided by PLA2-II/cPLA2 seems not to be the rate limiting step in PGE2 (a prostaglandin/mitogen) formation via COX-2 and PLA2-II plays a minor or no role in human colorectal carcinogenesis.
|
9858896 |
1998 |
|
Colorectal Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
|
9858896 |
1998 |
|
Malignant neoplasm of colon and/or rectum
|
0.070 |
Biomarker
|
disease |
BEFREE |
Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer.
|
9858896 |
1998 |
|
Sepsis
|
0.210 |
Biomarker
|
disease |
RGD |
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
|
9879654 |
1998 |
|
Amyotrophic Lateral Sclerosis
|
0.310 |
Biomarker
|
disease |
BEFREE |
We investigated the cellular localization of cytosolic phospholipase A(2) in the CNS following: (1) focal and global cerebral ischemia, (2) facial nerve axotomy, (3) human cases of Alzheimer's disease, (4) transgenic mice overexpressing mutant superoxide dismutase, a mouse model of amyotrophic lateral sclerosis, and (5) transgenic mice overexpressing mutant amyloid precursor protein, which exhibits age-related amyloid deposition characteristic of Alzheimer's disease.
|
10417811 |
1999 |